Source:http://linkedlifedata.com/resource/pubmed/id/21353177
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2011-2-28
|
| pubmed:abstractText |
Preclinical and clinical evidence suggests that bisphosphonates have anticancer activities both within and outside bone. Early clinical trials of bisphosphonates provided evidence for antimyeloma effects in exploratory analyses in high-risk subsets, and recent trials of zoledronic acid (ZOL) have provided further support of antimyeloma activity The MRC Myeloma IX trial is an innovative 2 x 2 factorial trial comparing ZOL and clodronate (CLO) in patients with newly diagnosed multiple myeloma receiving either intensive or non-intensive therapy regimens. Results showed that ZOL significantly reduced skeletal morbidity and significantly improved both progression-free and overall survival versus CLO. Notably, the survival benefit with ZOL remained significant after adjustment for skeletal-related events, consistent with clinically meaningful antimyeloma activity. Further analyses of these data will provide greater insight into ZOL interactions with primary treatment regimens for multiple myeloma.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bone Density Conservation Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Clodronic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Diphosphonates,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/zoledronic acid
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1879-0461
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
77 Suppl 1
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
S24-30
|
| pubmed:meshHeading |
pubmed-meshheading:21353177-Animals,
pubmed-meshheading:21353177-Bone Density Conservation Agents,
pubmed-meshheading:21353177-Bone and Bones,
pubmed-meshheading:21353177-Breast Neoplasms,
pubmed-meshheading:21353177-Clodronic Acid,
pubmed-meshheading:21353177-Diphosphonates,
pubmed-meshheading:21353177-Drug Evaluation, Preclinical,
pubmed-meshheading:21353177-Female,
pubmed-meshheading:21353177-Humans,
pubmed-meshheading:21353177-Imidazoles,
pubmed-meshheading:21353177-Male,
pubmed-meshheading:21353177-Mice,
pubmed-meshheading:21353177-Multiple Myeloma,
pubmed-meshheading:21353177-Prostatic Neoplasms,
pubmed-meshheading:21353177-Randomized Controlled Trials as Topic,
pubmed-meshheading:21353177-Research Design,
pubmed-meshheading:21353177-Risk Factors,
pubmed-meshheading:21353177-Treatment Outcome
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?
|
| pubmed:affiliation |
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, United Kingdom. Gareth.Morgan@icr.ac.uk
|
| pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|